Clinical Trials Insurance in Australia: What Sponsors, CROs and Sites Need Before First Patient In

Every clinical trial in Australia sits on a stack of contracts, approvals and insurance certificates that all need to line up before the first patient walks in the door. Miss a layer and the trial doesn’t start.

Clinical trials insurance is often mistaken for a single policy that can be ticked off. It isn’t. It’s a deed-plus-insurance structure that has to satisfy the TGA, an HREC, a hospital or research site, and in many cases an overseas parent company and a CRO. Each of those gates looks at the paperwork slightly differently.

According to the Australian Clinical Trials Portal, Australia runs thousands of trials across every phase and therapeutic area each year, spanning pharmaceutical, biotech, medical device and investigator-initiated research. The regulatory framework is well established - but the insurance side is where sponsors, CROs and sites most often run into trouble.

Key Takeaways:

• Clinical trials insurance isn’t one policy - it’s a deed plus a stack of insurance covers that sponsors, CROs and sites each need
• The Medicines Australia Standard Form Indemnity is a contract, not an insurance policy - the sponsor’s clinical trials cover sits behind it
• Most standard product liability policies exclude investigational products, so a specialist extension or standalone cover is usually required
• HRECs typically check insurance as part of trial approval, and sites require a certificate before the agreement is signed
• No-fault compensation for participants injured in the trial is a sponsor obligation under Medicines Australia guidelines

What is clinical trials insurance?

Clinical trials insurance is specialist liability cover taken out by the trial sponsor to respond to claims, participant injury compensation and legal defence costs arising from a clinical trial. It usually combines public liability, product liability on the investigational product, professional indemnity for investigator and CRO activities, and a no-fault compensation section that responds in line with Medicines Australia guidelines.

It’s different to the cover a standard biotech, medical device or pharmaceutical business normally carries day to day. A general public liability and product liability policy will usually exclude clinical trials and investigational products entirely. Sponsors need either a dedicated clinical trials policy or a properly drafted extension to their existing life sciences insurance programme.

A general business pack or off-the-shelf liability policy typically won’t cover a clinical trial. Checking this early in the trial design phase, rather than weeks before first patient in, makes a material difference to both the cover options and the premium outcome. Once ethics approval is locked in and site agreements are in flight, there’s limited runway left to shop the market properly.

Who needs clinical trials insurance in Australia?

The short answer is every party with skin in the trial. In practice, that’s the sponsor, the CRO, each site, and the individual investigators. Each needs something slightly different.

Sponsors

The sponsor carries the primary insurance obligation for the trial. That includes product liability on the investigational product, no-fault compensation for participants, and legal defence for the sponsor itself and typically for the site, CRO and investigators under the indemnity deed. Limits of $20M are common for pharmaceutical and medical device trials, though smaller academic or investigator-initiated studies often sit lower.

Australian sponsors include locally based biotech and medical device companies, and overseas sponsors who typically appoint an Australian legal representative. Overseas-sponsored trials often need a policy structure that recognises both the local and parent entity, which is one of the things underwriters look closely at.

Contract Research Organisations (CROs)

A CRO running trial activities on behalf of a sponsor needs its own professional indemnity and public liability cover for the work it performs - protocol management, monitoring, data handling, pharmacovigilance. CROs are also named as indemnified parties under most sponsor deeds, but that contractual indemnity is not a substitute for the CRO carrying its own insurance. Sponsors and sites will almost always ask for a CRO certificate of currency separately.

Sites (hospitals, clinics, research institutes)

The site carries its own liability cover for premises, staff and general operations. For private clinics and allied health research sites, this often ties back to a broader medical malpractice and business insurance programme. Public hospitals and universities usually sit under government or statutory arrangements, but private sites - including commercial Phase I units, specialist oncology clinics, GP-based research networks and cosmetic / dermatological trial sites - need their own cover and typically rely on the sponsor indemnity for trial-specific exposures.

Investigators

Individual doctors conducting the trial are usually indemnified by the sponsor for trial-related activities and carry their own medical defence organisation (MDO) cover for clinical practice. Allied health investigators sit under their professional indemnity cover, usually written as part of the site’s programme or their own practice insurance.

What does the Medicines Australia Standard Form Indemnity cover?

The Medicines Australia Standard Form Indemnity is a deed signed between the sponsor and the trial site. It’s the contractual document that allocates risk for the trial between the parties - it’s not an insurance policy.

Under the standard form, the sponsor agrees to indemnify the site (and typically the investigators and institution) against claims arising from the trial, subject to the usual carve-outs for site negligence, protocol deviation and breach of good clinical practice. It also sets out the sponsor’s obligation to compensate participants injured as a result of their trial participation in line with the Medicines Australia compensation guidelines.

Here’s the part sponsors often miss. The deed creates a legal obligation. The clinical trials insurance policy is what lets the sponsor actually meet that obligation when a claim hits. A deed without matching insurance behind it is a promise the sponsor can’t afford to keep.

The Medicines Australia clinical trials resources include the standard indemnity form, the compensation guidelines, and the code of conduct - all publicly available. Most sites will expect the sponsor to use the standard form with minimal amendments, and will usually ask legal to review anything that drifts from it.

What do the TGA and HRECs require before a trial starts?

Australian clinical trials are regulated by the TGA through two schemes, depending on the risk profile of the therapeutic good.

The Clinical Trial Notification (CTN) scheme is the default pathway. The sponsor notifies the TGA of the trial, the HREC has primary responsibility for approving it, and the institution has responsibility for the conduct of the trial at the site. Most trials in Australia run under the CTN scheme.

The Clinical Trial Approval (CTA) scheme applies where the TGA wants to review the product scientifically before approving the trial - typically for higher-risk or novel therapeutic goods. CTA trials often have a more complex risk profile, which can flow through to the insurance placement.

HREC insurance checks

Human Research Ethics Committees operate under the NHMRC National Statement on Ethical Conduct in Human Research. HRECs review the full trial package, including the indemnity and insurance arrangements. Most will ask to see a certificate of currency, the Medicines Australia indemnity deed, and the participant information and consent form (PICF) language covering insurance and compensation.

One issue that can hold up HREC approval is a certificate of currency that doesn’t clearly evidence the no-fault compensation cover in line with Medicines Australia guidelines. The underlying policy can be perfectly adequate, but if the certificate wording doesn’t spell it out the committee can send it back. Getting the certificate drafted correctly from the outset avoids that cycle.

Site agreements

Once an HREC has approved the trial, the sponsor (or CRO acting for the sponsor) signs a site agreement with each research site. Site agreements almost always require a certificate of currency showing the sponsor’s clinical trials cover, limits, no-fault compensation section, and the site as an indemnified party. A mismatch between the deed and the certificate will usually hold the agreement up until it’s fixed.

How does no-fault compensation work in Australia?

Australia doesn’t have a single statutory scheme for clinical trial participant compensation. Instead, sponsors are expected to provide compensation on a no-fault basis in line with the Medicines Australia Guidelines for Compensation for Injury Resulting from Participation in a Company-Sponsored Clinical Trial.

“No fault” means the participant doesn’t need to prove sponsor or investigator negligence to receive compensation. If they’ve suffered an injury as a result of the trial, the sponsor is expected to compensate them. That sits alongside the sponsor’s general legal liability if negligence is later established.

Clinical trials insurance policies are written to respond to both. The no-fault section typically covers medical expenses and rehabilitation, lost earnings, and in more serious cases, lump sum compensation assessed against tort principles. The legal liability section responds to any claim brought against the sponsor, CRO, site or investigators arising from the trial.

This is where policy wording matters a lot. Not every policy marketed as “clinical trials” cover includes a fit-for-purpose no-fault section, and the gap often isn’t apparent until an HREC queries it or a participant is injured.

Does product liability insurance cover investigational products?

Usually no, not under a standard policy. Most general product liability policies contain an exclusion for investigational products, pre-approval medicines, unregistered therapeutic goods, or products supplied under a clinical trial protocol.

This is one of the most common coverage gaps in clinical trial insurance arrangements. A biotech or medical device founder may have solid product liability cover for their on-market products (or plans to), but the pipeline product running a trial sits outside the policy. A specialist life sciences product liability extension, or a dedicated clinical trials policy, is what typically fills that gap.

The same issue flows through to post-trial access and compassionate use. If the trial product is supplied to participants after the trial closes (or to participants outside the protocol on compassionate grounds), the sponsor’s insurance needs to contemplate that exposure too. Post-trial access is increasingly common and isn’t always well covered by the clinical trials policy itself.

What coverage gaps should you watch for at placement?

When a sponsor’s existing programme or a CRO’s cover is reviewed against a planned trial, these are the recurring gaps worth pressure-testing.

Territorial scope for multi-site and international trials

Multi-site trials that span Australia, New Zealand and overseas jurisdictions need a policy with the right territorial limits. A policy written for an Australian-only trial won’t respond to a US or EU site. For sponsors running global programmes, a worldwide policy (often excluding US claims, which are priced separately) is usually the right structure.

Decentralised and hybrid trial components

More trials now include remote monitoring, wearable data capture, telehealth consultations and home-based dosing. Older policy wordings weren’t drafted with decentralised clinical trial (DCT) components in mind, and coverage for off-site activity can be ambiguous. It’s worth raising specifically at placement so the wording can be negotiated where it matters.

Biosamples, tissue and data handling

Biosample collection, biobanking and human tissue handling carry their own liability tail - particularly where data protection, informed consent and cross-border transfer come into play. A clinical trials policy that doesn’t contemplate biosample handling may respond, but it may not. Specialist wordings are clearer.

Contract manufacturing gaps

Most sponsors don’t manufacture the investigational product themselves. They use a contract manufacturer (CMO). Responsibility for product defects at the CMO level often sits outside the sponsor’s clinical trials cover - it’s a product liability question on the CMO’s policy, which the sponsor may or may not be a named interest on. This is one to flag specifically and structure around rather than assume will respond.

Post-trial and compassionate use access

As above, continuing supply to participants after the trial ends needs explicit coverage. It’s sometimes a simple endorsement, sometimes a separate arrangement.

What should sponsors and CROs do before first patient in?

A broker’s checklist for the pre-trial stage.

Work through this before the HREC submission if possible, not after. Insurance gaps identified during ethics review are almost always solvable but they cost weeks and sometimes a re-submission.

What drives the premium for clinical trials insurance?

There isn’t a simple rate card. Premium reflects the risk profile of the specific trial and the sponsor. The main drivers underwriters look at:

• Phase - Phase I first-in-human trials sit at a different risk level to Phase III and Phase IV studies, and pricing reflects it
• Therapeutic area and molecule class - oncology, cardiovascular, CNS, biologics, gene therapies, advanced therapies all price differently
• Participant numbers and vulnerability - paediatric, pregnant, oncology and other vulnerable populations carry higher exposure
• Territorial footprint - Australia-only trials price differently to global programmes; US sites materially increase premium
• Sponsor experience and governance - first-time sponsors usually price higher than experienced sponsors with a clean trial history
• Limits required - $5M, $10M, $20M and higher limits are all achievable through specialist markets, but drive premium accordingly

For small academic and investigator-initiated trials, limits are often lower and premium sits modestly. For commercial Phase II and III programmes, the numbers scale quickly. We don’t publish indicative premiums because the range is simply too wide to be useful - but if you give us the trial parameters, we’ll get you a realistic indication quickly.

How Tank Insurance can help

We specialise in placing life sciences insurance for Australian businesses that sit outside standard market appetite, with access to specialist markets that write clinical trial exposures alongside the broader life sciences stack.

We’ve placed cover across a range of life sciences risks, including biomedical R&D consultancies, scientific research and data consultancies, therapeutic medical device distribution and hire, dermatologically tested consumer products and imported children’s products. On the product liability side we’ve reached limits of $20M through specialist markets. A biomedical engineering consultant case study and the scientific data consultancy case study walk through how the placement works in practice.

Markets we place through on life sciences risks include specialist underwriters like Keystone Underwriting, SURA Life Sciences, Australasia Underwriting, Berkley, CFC and various Lloyd’s syndicates. These markets understand clinical trial risk, investigational product exposure, Medicines Australia indemnity structures and the Australian regulatory framework in a way that standard insurers typically aren’t set up for.

If you’re designing a trial, signing off on a CRO contract, or reviewing your existing life sciences programme against a new study, it’s worth a conversation early rather than two weeks before first patient in. Our life sciences insurance page covers the full range, and the sibling piece on product recall insurance covers the adjacent recall exposure most life sciences businesses also carry.

Call us on 02 9000 1155 or email [email protected].

Frequently Asked Questions

Do you need insurance to run a clinical trial in Australia?

Yes, in practice. Clinical trial insurance isn’t mandated in a single piece of legislation, but it’s required in practice by every functioning gate in the system. HRECs check insurance as part of approval, site agreements require a certificate of currency, and the Medicines Australia Standard Form Indemnity assumes the sponsor sits behind an insurance policy. No certificate usually means no first patient in.

What is the Medicines Australia standard indemnity?

It’s a deed signed between the sponsor and the trial site setting out the sponsor’s obligation to indemnify the site for claims arising from the trial and to compensate participants injured as a result of trial participation. It’s a contractual document, not an insurance policy. The sponsor’s clinical trials insurance is what actually responds behind the deed when a claim hits.

Who pays if a clinical trial participant is injured in Australia?

The trial sponsor is expected to compensate participants injured as a result of the trial, typically on a no-fault basis in line with the Medicines Australia Guidelines for Compensation for Injury Resulting from Participation in a Company-Sponsored Clinical Trial. Sponsors arrange clinical trials insurance that responds to these payments and to any legal claims brought against the sponsor, CRO, site or investigators.

Does product liability insurance cover investigational products?

Most standard product liability policies exclude investigational products, pre-approval medicines and unregistered therapeutic goods. Specialist clinical trials insurance, or a life sciences product liability extension, is needed to cover the investigational product during the trial and often in the compassionate use or post-trial access window.

What is the difference between CTN and CTA trials in Australia?

The TGA regulates clinical trials through two schemes. Under the CTN scheme, the HREC approves the trial and the sponsor simply notifies the TGA - this covers most trials in Australia. The CTA scheme applies to higher-risk or novel therapeutic goods where the TGA conducts a full scientific review before the trial starts. Insurance requirements are broadly similar under both, though CTA trials often involve more complex risk profiles.

---

This is general information only and does not take into account your objectives, financial situation, or needs. You should consider whether the information is appropriate for you and read the relevant Product Disclosure Statement (PDS) before making any decisions about insurance products.